Related Experiment Video
Updated: Jun 3, 2026
Live Imaging and Analysis of Muscle Contractions in Drosophila Embryo
Published on: July 9, 2019
Dystroglycanopathies: coming into focus
Caroline Godfrey1, A Reghan Foley, Emma Clement
1Dubowitz Neuromuscular Centre, UCL Institute of Child Health and the Great Ormond Street Hospital for Children, Guilford Street, University College London, United Kingdom.
Abstract:
A common group of muscular dystrophies is associated with the aberrant glycosylation of α-dystroglycan. These clinically heterogeneous disorders, collectively termed dystroglycanopathies, are often associated with central nervous system and more rarely eye pathology. Defects in a total of eight putative and demonstrated glycosyltransferases or accessory proteins of glycosyltransferases have been shown to cause a dystroglycanopathy phenotype. In recent years the systematic analysis of large patient cohorts has uncovered a complex relationship between the underlying genetic defect and the resulting clinical phenotype. These studies have also drawn attention to the high proportion of patients that remain without a genetic diagnosis implicating novel genes in the pathogenesis of dystroglycanopathies. Recent glycomic analyses of α-dystroglycan have reported complex patterns of glycan composition and have uncovered novel glycan modifications. The exact glycan synthesis and modification pathways involved, as well as their role in ligand binding, remain only partially characterised. This review will focus on recent studies that have extended our knowledge of the mechanisms underlying dystroglycanopathies and have further characterised this patient population.
Insights
Dystroglycanopathies, a group of muscular dystrophies, result from abnormal glycosylation of α-dystroglycan. Research highlights complex genetic links and identifies the need for novel gene discovery in these rare diseases.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- Muscular dystrophies linked to aberrant α-dystroglycan glycosylation are known as dystroglycanopathies.
- These disorders exhibit clinical heterogeneity, often involving central nervous system and ocular pathologies.
- Defects in eight identified glycosyltransferases or their accessory proteins cause dystroglycanopathy phenotypes.
Purpose of the Study:
- To review recent advancements in understanding dystroglycanopathy mechanisms.
- To characterize the patient population and genetic underpinnings of these disorders.
- To explore novel glycan modifications and their role in α-dystroglycan function.
Main Methods:
- Systematic analysis of large patient cohorts.
- Review of glycomic analyses of α-dystroglycan.
- Examination of genetic defects and their correlation with clinical phenotypes.
Main Results:
- Complex genotype-phenotype relationships in dystroglycanopathies have been uncovered.
- A significant proportion of patients lack a genetic diagnosis, suggesting undiscovered causative genes.
- Novel glycan modifications on α-dystroglycan have been identified, with pathways still under investigation.
Conclusions:
- Recent studies have expanded knowledge of dystroglycanopathy pathogenesis.
- Further research is needed to fully elucidate glycan synthesis, modification, and ligand-binding roles.
- Continued genetic analysis is crucial for diagnosing and understanding the full spectrum of dystroglycanopathies.
Related Concept Videos
01:05Proteoglycans
01:05Desmosomes
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
01:22Lysosomal Hydrolases
01:26Type I Diabetes II: Pathophysiology
03:14Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...